Janux Therapeutics Statistics Share Statistics Janux Therapeutics has 60.09M
shares outstanding. The number of shares has increased by 3.97%
in one year.
Shares Outstanding 60.09M Shares Change (YoY) 3.97% Shares Change (QoQ) 1.55% Owned by Institutions (%) 99.99% Shares Floating 54.31M Failed to Deliver (FTD) Shares 7,931 FTD / Avg. Volume 1%
Short Selling Information The latest short interest is 8.3M, so 13.81% of the outstanding
shares have been sold short.
Short Interest 8.3M Short % of Shares Out 13.81% Short % of Float 19.85% Short Ratio (days to cover) 12.88
Valuation Ratios The PE ratio is -41.71 and the forward
PE ratio is -7.74.
Janux Therapeutics's PEG ratio is
13.76.
PE Ratio -41.71 Forward PE -7.74 PS Ratio 271.8 Forward PS 251.8 PB Ratio 2.81 P/FCF Ratio -65.15 PEG Ratio 13.76
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Janux Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 59.21,
with a Debt / Equity ratio of 0.02.
Current Ratio 59.21 Quick Ratio 59.21 Debt / Equity 0.02 Debt / EBITDA -0.23 Debt / FCF -0.52 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $116.35K Profits Per Employee $-758.18K Employee Count 91 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -46.69% in the
last 52 weeks. The beta is 2.82, so Janux Therapeutics's
price volatility has been higher than the market average.
Beta 2.82 52-Week Price Change -46.69% 50-Day Moving Average 23.91 200-Day Moving Average 30.72 Relative Strength Index (RSI) 51.93 Average Volume (20 Days) 790,803
Income Statement In the last 12 months, Janux Therapeutics had revenue of 10.59M
and earned -68.99M
in profits. Earnings per share was -1.28.
Revenue 10.59M Gross Profit 8.53M Operating Income -98.85M Net Income -68.99M EBITDA -98.85M EBIT -98.85M Earnings Per Share (EPS) -1.28
Full Income Statement Balance Sheet The company has 430.61M in cash and 23.02M in
debt, giving a net cash position of 407.58M.
Cash & Cash Equivalents 430.61M Total Debt 23.02M Net Cash 407.58M Retained Earnings -237.76M Total Assets 1.03B Working Capital 984.17M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -43.81M
and capital expenditures -359K, giving a free cash flow of -44.17M.
Operating Cash Flow -43.81M Capital Expenditures -359K Free Cash Flow -44.17M FCF Per Share -0.82
Full Cash Flow Statement Margins Gross margin is 80.54%, with operating and profit margins of -933.58% and -651.62%.
Gross Margin 80.54% Operating Margin -933.58% Pretax Margin -651.62% Profit Margin -651.62% EBITDA Margin -933.58% EBIT Margin -933.58% FCF Margin -417.2%
